<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2448-9190</journal-id>
<journal-title><![CDATA[Revista alergia México]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. alerg. Méx.]]></abbrev-journal-title>
<issn>2448-9190</issn>
<publisher>
<publisher-name><![CDATA[Colegio Mexicano de Inmunología Clínica y Alergia A.C.]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2448-91902025000400382</article-id>
<article-id pub-id-type="doi">10.29262/ram.v72i4.1547</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Experiencia en el cambio de un anticuerpo monoclonal en un paciente con dermatitis atópica grave resistente al tratamiento convencional: de dupilumab a abrocitinib. Reporte de un caso]]></article-title>
<article-title xml:lang="en"><![CDATA[Experience in switching monoclonal antibodies in a patient with severe refractory atopic dermatitis: from Dupilumab to Abrocitinib. Case report]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Palafox-Olvera]]></surname>
<given-names><![CDATA[Ariadna]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Moncayo-Coello]]></surname>
<given-names><![CDATA[Carol Vivian]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Castillo-Narváez]]></surname>
<given-names><![CDATA[Gloria]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Hospital Juárez de México Servicio de Alergia e Inmunología ]]></institution>
<addr-line><![CDATA[Ciudad de México ]]></addr-line>
<country>México</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Hospital Juárez de México Servicio de Alergia e Inmunología ]]></institution>
<addr-line><![CDATA[Ciudad de México ]]></addr-line>
<country>México</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Hospital Juárez de México Servicio de Alergia e Inmunología ]]></institution>
<addr-line><![CDATA[Ciudad de México ]]></addr-line>
<country>México</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>12</month>
<year>2025</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>12</month>
<year>2025</year>
</pub-date>
<volume>72</volume>
<numero>4</numero>
<fpage>382</fpage>
<lpage>385</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S2448-91902025000400382&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S2448-91902025000400382&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S2448-91902025000400382&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  Antecedentes: La dermatitis atópica es una enfermedad inflamatoria crónica que afecta la piel y se caracteriza por prurito intenso y eccema.Requiere de terapias sistémicas y el uso de tratamientos novedosos, como Dupilumab o inhibidores de Janus Kinasa. La aprobación de estos medicamentos ha venido a revolucionar el tratamiento en los últimos años.  Reporte de caso: Se expone el caso de paciente masculino de 22 años, con dermatitis atópica grave, resistente al tratamiento con inmunosupresor y su evolución al iniciar el cambio con anticuerpos monoclonales.  Conclusiones: Los anticuerpos monoclonales son terapias avanzadas y novedosas que han demostrado eficacia en pacientes con dermatitis atópica moderada a grave. En este artículo presentamos el caso de un paciente que, con cambio de molécula, presenta mejoría en su evolución y calidad de vida, demostrando una adecuada respuesta de acuerdo con el índice de puntuación de dermatitis (SCORAD) tras manejo con Abrocitinib.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Background: Atopic dermatitis is a chronic inflammatory disease that affects the skin and is characterized by intense pruritus and eczema. It requires systemic therapies and the use of novel treatments, such as Dupilumab and Janus kinase inhibitors. The approval of these drugs has revolutionized treatment during the last years.  Case report: We present a case of a patient with severe atopic dermatitis, refractory to immunosuppressive treatment and his evolution after starting treatment with monoclonal antibodies.  Conclusions: Monoclonal antibodies are advanced and novel therapies that have demonstrated efficacy in patients with moderate to severe atopic dermatitis. In this article we present a case of a patient with switch of treatment, who had improvement in his evolution and quality of life, demonstrating an adequate response according to the dermatitis scoring index (SCORAD) after treatment with Abrocitinib.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Dermatitis atópica]]></kwd>
<kwd lng="es"><![CDATA[Anticuerpos monoclonales]]></kwd>
<kwd lng="es"><![CDATA[Dupilumab]]></kwd>
<kwd lng="es"><![CDATA[Abrocitinib]]></kwd>
<kwd lng="es"><![CDATA[Inmunosupresores]]></kwd>
<kwd lng="en"><![CDATA[Atopic dermatitis]]></kwd>
<kwd lng="en"><![CDATA[Monoclonal antibodies]]></kwd>
<kwd lng="en"><![CDATA[Dupilumab]]></kwd>
<kwd lng="en"><![CDATA[Abrocitinib]]></kwd>
<kwd lng="en"><![CDATA[Immunosuppressants]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Simpson]]></surname>
<given-names><![CDATA[EL]]></given-names>
</name>
<name>
<surname><![CDATA[Silverberg]]></surname>
<given-names><![CDATA[JI]]></given-names>
</name>
<name>
<surname><![CDATA[Thyssen]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Efficacy and Safety of Abrocitinib in Patients with Severe and/or Difficult-to-Treat Atopic Dermatitis: A Post Hoc Analysis of the Randomized Phase 3 JADE COMPARE Trial]]></article-title>
<source><![CDATA[Am J Clin Dermatol]]></source>
<year>2023</year>
<volume>24</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>609-21</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Perche]]></surname>
<given-names><![CDATA[PO]]></given-names>
</name>
<name>
<surname><![CDATA[Cook]]></surname>
<given-names><![CDATA[MK]]></given-names>
</name>
<name>
<surname><![CDATA[Feldman]]></surname>
<given-names><![CDATA[SR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Abrocitinib: A New FDA-Approved Drug for Moderate-to-Severe Atopic Dermatitis]]></article-title>
<source><![CDATA[Ann Pharmacother]]></source>
<year>2023</year>
<volume>57</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>86-98</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Silverberg]]></surname>
<given-names><![CDATA[JI]]></given-names>
</name>
<name>
<surname><![CDATA[Thyssen]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
<name>
<surname><![CDATA[Fahrbach]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Comparative efficacy and safety of systemic therapies used in moderate-to-severe atopic dermatitis: a systematic literature review and network meta-analysis]]></article-title>
<source><![CDATA[J Eur Acad Dermatol Venereol]]></source>
<year>2021</year>
<volume>35</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>1797-810</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ferreira]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Guttman-Yassky]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Torres]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Selective JAK1 Inhibitors for the Treatment of Atopic Dermatitis: Focus on Upadacitinib and Abrocitinib]]></article-title>
<source><![CDATA[Am J Clin Dermatol]]></source>
<year>2020</year>
<volume>21</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>783-98</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wan]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Jia]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Xia]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Comparative efficacy and safety of Abrocitinib, baricitinib, and upadacitinib for moderate-to-severe atopic dermatitis: A network meta-analysis]]></article-title>
<source><![CDATA[Dermatol Ther]]></source>
<year>2022</year>
<volume>35</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>e15636</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Drucker]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[Morra]]></surname>
<given-names><![CDATA[DE]]></given-names>
</name>
<name>
<surname><![CDATA[Prieto-Merino]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Systemic Immunomodulatory Treatments for Atopic Dermatitis: Update of a Living Systematic Review and Network Meta-analysis]]></article-title>
<source><![CDATA[JAMA Dermatol]]></source>
<year>2022</year>
<volume>158</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>523-32</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tsai]]></surname>
<given-names><![CDATA[YC]]></given-names>
</name>
<name>
<surname><![CDATA[Tsai]]></surname>
<given-names><![CDATA[TF]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Successful treatment of atopic dermatitis by switching from upadacitinib to Abrocitinib: a case report]]></article-title>
<source><![CDATA[Eur J Dermatol]]></source>
<year>2023</year>
<volume>33</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>699-701</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Davis]]></surname>
<given-names><![CDATA[DMR]]></given-names>
</name>
<name>
<surname><![CDATA[Drucker]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[Alikhan]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Guidelines of care for the management of atopic dermatitis in adults with phototherapy and systemic therapies]]></article-title>
<source><![CDATA[J Am Acad Dermatol]]></source>
<year>2024</year>
<volume>90</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>e43-56</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bieber]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Simpson]]></surname>
<given-names><![CDATA[EL]]></given-names>
</name>
<name>
<surname><![CDATA[Silverberg]]></surname>
<given-names><![CDATA[JI]]></given-names>
</name>
<name>
<surname><![CDATA[Thaçi]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Abrocitinib versus placebo or Dupilumab for atopic dermatitis]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2021</year>
<volume>384</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>1101-12</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chu]]></surname>
<given-names><![CDATA[DK]]></given-names>
</name>
<name>
<surname><![CDATA[Schneider]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<collab>AAAAI/ACAAI JTF Atopic Dermatitis Guideline Panel</collab>
<article-title xml:lang=""><![CDATA[Atopic dermatitis (eczema) guidelines: 2023 American Academy of Allergy, Asthma and Immunology/American College of Allergy, Asthma and Immunology Joint Task Force on Practice Parameters GRADE- and Institute of Medicine-based recommendations]]></article-title>
<source><![CDATA[Ann Allergy Asthma Immunol]]></source>
<year>2024</year>
<volume>132</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>274-312</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Shi]]></surname>
<given-names><![CDATA[VY]]></given-names>
</name>
<name>
<surname><![CDATA[Bhutani]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Fonacier]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Phase 3 efficacy and safety of Abrocitinib in adults with moderate-to-severe atopic dermatitis after switching from Dupilumab (JADE EXTEND)]]></article-title>
<source><![CDATA[J Am Acad Dermatol]]></source>
<year>2022</year>
<volume>87</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>351-8</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lasheras-Pérez]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Palacios-Díaz]]></surname>
<given-names><![CDATA[RD]]></given-names>
</name>
<name>
<surname><![CDATA[Pozuelo-Ruíz]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Torres-Navarro]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Switching from Dupilumab to tralokinumab in patients with atopic dermatitis due to inefficacy or side effects]]></article-title>
<source><![CDATA[Int J Dermatol]]></source>
<year>2024</year>
<volume>63</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>105-7</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>1.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Simpson]]></surname>
<given-names><![CDATA[EL]]></given-names>
</name>
<name>
<surname><![CDATA[Silverberg]]></surname>
<given-names><![CDATA[JI]]></given-names>
</name>
<name>
<surname><![CDATA[Thyssen]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Efficacy and Safety of Abrocitinib in Patients with Severe and/or Difficult-to-Treat Atopic Dermatitis: A Post Hoc Analysis of the Randomized Phase 3 JADE COMPARE Trial]]></article-title>
<source><![CDATA[Am J Clin Dermatol]]></source>
<year>2023</year>
<volume>24</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>609-21</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>2.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Perche]]></surname>
<given-names><![CDATA[PO]]></given-names>
</name>
<name>
<surname><![CDATA[Cook]]></surname>
<given-names><![CDATA[MK]]></given-names>
</name>
<name>
<surname><![CDATA[Feldman]]></surname>
<given-names><![CDATA[SR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Abrocitinib: A New FDA-Approved Drug for Moderate-to-Severe Atopic Dermatitis]]></article-title>
<source><![CDATA[Ann Pharmacother]]></source>
<year>2023</year>
<volume>57</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>86-98</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>3.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Silverberg]]></surname>
<given-names><![CDATA[JI]]></given-names>
</name>
<name>
<surname><![CDATA[Thyssen]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
<name>
<surname><![CDATA[Fahrbach]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Comparative efficacy and safety of systemic therapies used in moderate-to-severe atopic dermatitis: a systematic literature review and network meta-analysis]]></article-title>
<source><![CDATA[J Eur Acad Dermatol Venereol]]></source>
<year>2021</year>
<volume>35</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>1797-810</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>4.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ferreira]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Guttman-Yassky]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Torres]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Selective JAK1 Inhibitors for the Treatment of Atopic Dermatitis: Focus on Upadacitinib and Abrocitinib]]></article-title>
<source><![CDATA[Am J Clin Dermatol]]></source>
<year>2020</year>
<volume>21</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>783-98</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>5.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wan]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Jia]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Xia]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Comparative efficacy and safety of Abrocitinib, baricitinib, and upadacitinib for moderate-to-severe atopic dermatitis: A network meta-analysis]]></article-title>
<source><![CDATA[Dermatol Ther]]></source>
<year>2022</year>
<volume>35</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>e15636</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
